Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine plus favipiravir versus hydroxychloroquine plus Kaletra in hospitalized COVID-19 patients
IRCT20150808023559N20Phase 2Completed
- Sponsor
- Ardabil University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of favipiravir, hydroxychloroquine, lopinavir, ritonavir and lopinavir + ritonavir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Ardabil University of Medical Sciences. Primary endpoints: Mortality and Length of stay in hospital. Started Apr 2020; status: completed.
02
Drugs
favipiravirhydroxychloroquinelopinavirritonavirlopinavir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20150808023559N20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150808023559N20.